|
|
Volumn 15, Issue 2, 2013, Pages
|
|
Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data
a
b
OPTUM
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BIOLOGICAL PRODUCT;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
ETANERCEPT;
INFLIXIMAB;
ANTIRHEUMATIC AGENT;
ADULT;
ALGORITHM;
DRUG EFFICACY;
ERYTHROCYTE SEDIMENTATION RATE;
EVALUATION;
FEMALE;
HEALTH INSURANCE;
HUMAN;
INTERMETHOD COMPARISON;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
MEDICAL RECORD;
PREDICTIVE VALUE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RHEUMATOID ARTHRITIS;
SENSITIVITY ANALYSIS;
SENSITIVITY AND SPECIFICITY;
ARTHRITIS, RHEUMATOID;
COMPARATIVE EFFECTIVENESS;
INSURANCE;
MIDDLE AGED;
ALGORITHMS;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
COMPARATIVE EFFECTIVENESS RESEARCH;
FEMALE;
HUMANS;
INSURANCE CLAIM REVIEW;
MALE;
MIDDLE AGED;
SENSITIVITY AND SPECIFICITY;
|
|
EID: 84874806147
PISSN: 14786354
EISSN: 14786362
Source Type: Journal
DOI: 10.1186/ar4161 Document Type: Letter |
|
Times cited : (21)
|
|
References (3)
|
